Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 1 , Pages 84-92 , February 2010

In vitro proliferating cell models to study cytotoxicity of silica nanowires

  • Daniel C. Julien, BS

      Affiliations

    • Department of Animal and Veterinary Science, University of Idaho, Moscow, Idaho, USA
    • ,
  • Casey C. Richardson, BS

      Affiliations

    • Department of Mathematics and Statistics, University of New Mexico, Albuquerque, New Mexico, USA
    • ,
  • Miles F. Beaux II, BS

      Affiliations

    • Department of Physics, University of Idaho, Moscow, Idaho, USA
    • ,
  • David N. McIlroy, PhD

      Affiliations

    • Department of Physics, University of Idaho, Moscow, Idaho, USA
    • ,
  • Rodney A. Hill, PhD

      Affiliations

    • Department of Animal and Veterinary Science, University of Idaho, Moscow, Idaho, USA
    • Corresponding Author InformationCorresponding author. Department of Animal and Veterinary Science, University of Idaho, Moscow, ID 83844, USA.

Received 17 October 2008 ,Accepted 30 March 2009.

References 

  1. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed. 2007;18(3):241–268
  2. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat. 2005;4(4):363–374
  3. Yih TC, Wei C. Nanomedicine in cancer treatment. Nanomedicine. 2005;1(2):191–192
  4. Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Controlled Release. 2008;127(1):41–49
  5. Bharali DJ, Klejbor I, Stachowiak EK, Dutta P, Roy I, Kaur N, et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci U S A. 2005;102(32):11539–11544
  6. Fujita M, Lee BS, Khazenzon NM, Penichet ML, Wawrowsky KA, Patil R, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid. J Controlled Release. 2007;122(3):356–363
  7. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008;69(16):6652–6660
  8. Li Z, Zhu S, Gan K, Zhang Q, Zeng Z, Zhou Y, et al. Poly-L-lysine-modified silica nanoparticles: a potential oral gene delivery system. J Nanosci Nanotechnol. 2005;5(8):1199–1203
  9. Singh S, Nalwa HS. Nanotechnology and health safety—toxicity and risk assessments of nanostructured materials on human health. J Nanosci Nanotechnol. 2007;7(9):3048–3070
  10. Ye Z, Mahato RI. Role of nanomedicines in cell-based therapeutics. Nanomedicine: NBM. 2008;3(1):5–8
  11. Lanone S, Boczkowski J. Biomedical applications and potential health risks of nanomaterials: molecular mechanisms. Curr Mol Med. 2006;6(6):651–653
  12. Gwinn MR, Vallyathan V. Nanoparticles: health effects—pros and cons. Environ Health Perspect. 2006;114(12):1818–1825
  13. Yang H, Liu C, Yang D, Zhang H, Xi Z. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. J Appl Toxicol. 2009;29(1):69–78
  14. Kagan VE, Bayir H, Shvedova AA. Nanomedicine and nanotoxicology: two sides of the same coin. Nanomedicine: NBM. 2005;4:313–316
  15. Jin Y, Kannan S, Wu M, Zhao JX. Toxicity of luminescent silica nanoparticles to living cells. Chem Res Toxicol. 2007;20(8):1126–1133
  16. Lin W, Huang YW, Zhou XD, Ma Y. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol. 2006;217(3):252–259
  17. Barik TK, Sahu B, Swain V. Nanosilica-from medicine to pest control. Parasitol Res. 2008;103(2):253–258
  18. Chang JS, Chang KL, Hwang DF, Kong ZL. In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. Environ Sci Technol. 2007;41(6):2064–2068
  19. Chen M, von Mikecz A. Formation of nucleoplasmic protein aggregates impairs nuclear function in response to SiO2 nanoparticles. Exp Cell Res. 2005;305(1):51–62
  20. Salata O. Applications of nanoparticles in biology and medicine. J Nanobiotechnol. 2004;2(1):3
  21. Beaux IIMF, Wang L, Zhang D, Gangadean D, McIlroy DN, Kwon NH, et al. Fibronectin bonding to nanowires and their internalization by epithelial cells. J Biomed Nanotech. 2006;2:1–6
  22. Kwon NH, Beaux IIMF, Ebert C, Wang L, Lassiter BE, Park YH, et al. Nanowire-based delivery of Echerichia coli O157 Shiga toxin 1 A subunit into human and bovine cells. Nano Lett. 2007;7(9):2718–2723
  23. Qi S, Yi C, Chen W, Fong CC, Lee ST, Yang M. Effects of silicon nanowires on HepG2 cell adhesion and spreading. Chem BioChem. 2007;8:1115–1118
  24. Adili AA, Crowe S, Beaux IIMF, Cantrell TC, Shapiro PJ, McIlroy DN, et al. Differential cytotoxicity exhibited by silica nanowires and nanoparticles. Nanotoxicology. 2008;2(1):1–8
  25. Freshney RI. Freshney's culture of animal cells. New York: Wiley-Liss; 1999;
  26. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol. 1963;17:299–313
  27. Venkatasubramanian R, Henson MA, Forbes NS. Incorporating energy metabolism into a growth model of multicellular tumor spheroids. J Theor Biol. 2006;242(2):440–453
  28. Lima PDL, Vasconcellos MC, Montenegro RA, Sombra CM, Bahia MO, Costa-Lotufo LV, et al. Genotoxic and cytotoxic effects of iron sulfate in cultured human lymphocytes treated in different phases of cell cycle. Toxicol in Vitro. 2008;22(3):723–729
  29. Pause A, Lee S, Lonergan K, Klausner R. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A. 1998;95(3):993–998
  30. Festjens N, Berghe TV, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta. 2006;1757(9-10):1371–1387
  31. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760
  32. Kokta TA, Strat AL, Papasani MR, Szasz JI, Dodson MV, Hill RA. Regulation of lipid accumulation in 3T3-L1 cells: insulin-independent and combined effects of fatty acids and insulin. Animal. 2008;2:92–99
  33. Kim HK, Della-Fera M, Lin J, Baile CA. Docosahexaenoic acid inhibits adipocyte differentiation and induces apoptosis in 3T3-L1 preadipocytes. J Nutr. 2006;136(12):2965–2969
  34. Heron-Milhavet L, Karas M, Goldsmith CM, Baum BJ, LeRoith D. Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem. 2001;276(21):18185–18192
  35. Heron-Milhavet L, LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem. 2002;277(18):15600–15606
  36. Novosyadlyy R, Kurshan N, Lann D, Vijayakumar A, Yakar S, Leroith D. Insulin-like growth factor-I protects cells from ER stress-induced apoptosis via enhancement of the adaptive capacity of endoplasmic reticulum. Cell Death Differ. 2008;15(8):1304–1317
  37. Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J. PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene. 2003;22(27):4186–4193
  38. Toyoshima Y, Karas M, Yakar S, Dupont J, Lee H, LeRoith D. TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem. 2004;279(24):25898–25904
  39. Urso B, Niesler CU, O'Rahilly S, Siddle K. Comparison of anti-apoptotic signalling by the insulin receptor and IGF-I receptor in preadipocytes and adipocytes. Cell Signal. 2001;13(4):279–285
  40. Longo KA, Kennell JA, Ochocinska MJ, Ross SE, Wright WS, MacDougald OA. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem. 2002;277(41):38239–38244
  41. Zizola CF, Balana ME, Sandoval M, Calvo JC. Changes in IGF-I receptor and IGF-I mRNA during differentiation of 3T3-L1 preadipocytes. Biochimie. 2002;84(10):975–980
  42. Fleenor D, Arumugam R, Freemark M. Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I. Horm Res. 2006;66(3):101–110
  43. Kitanaka S, Sato U, Igarashi T. Regulation of human insulin, IGF-I, and multidrug resistance protein 2 promoter activity by hepatocyte nuclear factor (HNF)-1beta and HNF-1alpha and the abnormality of HNF-1beta mutants. J Endocrinol. 2007;192(1):141–147
  44. Geraghty KM, Chen S, Harthill JE, Ibrahim AF, Toth R, Morrice NA, et al. Regulation of multisite phosphorylation and 14-3-3 binding of AS160 in response to IGF-1, EGF, PMA and AICAR. Biochem J. 2007;407(2):231–241

 Dr. McIlroy is the Vice President of Research of GoNano Technologies, Inc. The current article has no relationship to GoNano.

 This work was supported by the University of Idaho Blue Ribbon BANTech initiative and by the National Science Foundation under award number CBET-0709468.

PII: S1549-9634(09)00098-7

doi: 10.1016/j.nano.2009.03.003

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 1 , Pages 84-92 , February 2010

Article Tools

* Image Usage & Resolution